These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 27348483)

  • 1. Ledipasvir/sofosbuvir-based treatment of patients with chronic genotype-1 HCV infection and cirrhosis: results from two Phase II studies.
    Lawitz E; Poordad F; Hyland RH; Wang J; Liu L; Dvory-Sobol H; Brainard DM; McHutchison JG; Gutierrez JA
    Antivir Ther; 2016; 21(8):679-687. PubMed ID: 27348483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis.
    Lim JK; Liapakis AM; Shiffman ML; Lok AS; Zeuzem S; Terrault NA; Park JS; Landis CS; Hassan M; Gallant J; Kuo A; Pockros PJ; Vainorius M; Akushevich L; Michael L; Fried MW; Nelson DR; Ben-Ari Z;
    Clin Gastroenterol Hepatol; 2018 Nov; 16(11):1811-1819.e4. PubMed ID: 29306043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS).
    Bourlière M; Bronowicki JP; de Ledinghen V; Hézode C; Zoulim F; Mathurin P; Tran A; Larrey DG; Ratziu V; Alric L; Hyland RH; Jiang D; Doehle B; Pang PS; Symonds WT; Subramanian GM; McHutchison JG; Marcellin P; Habersetzer F; Guyader D; Grangé JD; Loustaud-Ratti V; Serfaty L; Metivier S; Leroy V; Abergel A; Pol S
    Lancet Infect Dis; 2015 Apr; 15(4):397-404. PubMed ID: 25773757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial.
    Mizokami M; Yokosuka O; Takehara T; Sakamoto N; Korenaga M; Mochizuki H; Nakane K; Enomoto H; Ikeda F; Yanase M; Toyoda H; Genda T; Umemura T; Yatsuhashi H; Ide T; Toda N; Nirei K; Ueno Y; Nishigaki Y; Betular J; Gao B; Ishizaki A; Omote M; Mo H; Garrison K; Pang PS; Knox SJ; Symonds WT; McHutchison JG; Izumi N; Omata M
    Lancet Infect Dis; 2015 Jun; 15(6):645-53. PubMed ID: 25863559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial.
    Lawitz E; Poordad FF; Pang PS; Hyland RH; Ding X; Mo H; Symonds WT; McHutchison JG; Membreno FE
    Lancet; 2014 Feb; 383(9916):515-23. PubMed ID: 24209977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ledipasvir-sofosbuvir for treating Japanese patients with chronic hepatitis C virus genotype 2 infection.
    Asahina Y; Itoh Y; Ueno Y; Matsuzaki Y; Takikawa Y; Yatsuhashi H; Genda T; Ikeda F; Matsuda T; Dvory-Sobol H; Jiang D; Massetto B; Osinusi AO; Brainard DM; McHutchison JG; Kawada N; Enomoto N
    Liver Int; 2018 Sep; 38(9):1552-1561. PubMed ID: 29297980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label study.
    Lawitz E; Landis CS; Flamm SL; Bonacini M; Ortiz-Lasanta G; Huang J; Zhang J; Kirby BJ; De-Oertel S; Hyland RH; Osinusi AO; Brainard DM; Robson R; Maliakkal BJ; Gordon SC; Gane EJ
    Lancet Gastroenterol Hepatol; 2020 Oct; 5(10):918-926. PubMed ID: 32531259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response.
    Terrault NA; Zeuzem S; Di Bisceglie AM; Lim JK; Pockros PJ; Frazier LM; Kuo A; Lok AS; Shiffman ML; Ben Ari Z; Akushevich L; Vainorius M; Sulkowski MS; Fried MW; Nelson DR;
    Gastroenterology; 2016 Dec; 151(6):1131-1140.e5. PubMed ID: 27565882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A different perspective on sofosbuvir-ledipasvir treatment of patients with HCV genotype 1b cirrhosis: The ital-c network study.
    Barone M; Iannone A; Shahini E; Ippolito AM; Brancaccio G; Morisco F; Milella M; Messina V; Smedile A; Conti F; Gatti P; Santantonio T; Tundo P; Lauletta G; Napoli N; Masetti C; Termite AP; Francavilla R; Di Leo A; Pesce F; Andriulli A
    J Viral Hepat; 2018 Jan; 25(1):56-62. PubMed ID: 28787102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study.
    Abergel A; Asselah T; Metivier S; Kersey K; Jiang D; Mo H; Pang PS; Samuel D; Loustaud-Ratti V
    Lancet Infect Dis; 2016 Apr; 16(4):459-64. PubMed ID: 26803446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection.
    Abergel A; Metivier S; Samuel D; Jiang D; Kersey K; Pang PS; Svarovskaia E; Knox SJ; Loustaud-Ratti V; Asselah T
    Hepatology; 2016 Oct; 64(4):1049-56. PubMed ID: 27351341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection.
    Gane EJ; Hyland RH; An D; Svarovskaia E; Pang PS; Brainard D; Stedman CA
    Gastroenterology; 2015 Nov; 149(6):1454-1461.e1. PubMed ID: 26261007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ledipasvir-sofosbuvir: interferon-/ribavirin-free regimen for chronic hepatitis C virus infection.
    Smith MA; Chan J; Mohammad RA
    Ann Pharmacother; 2015 Mar; 49(3):343-50. PubMed ID: 25515863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful Retreatment of Chronic HCV Genotype-1 Infection With Ledipasvir and Sofosbuvir After Initial Short Course Therapy With Direct-Acting Antiviral Regimens.
    Wilson EM; Kattakuzhy S; Sidharthan S; Sims Z; Tang L; McLaughlin M; Price A; Nelson A; Silk R; Gross C; Akoth E; Mo H; Subramanian GM; Pang PS; McHutchison JG; Osinusi A; Masur H; Kohli A; Kottilil S
    Clin Infect Dis; 2016 Feb; 62(3):280-288. PubMed ID: 26521268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial.
    Manns M; Samuel D; Gane EJ; Mutimer D; McCaughan G; Buti M; Prieto M; Calleja JL; Peck-Radosavljevic M; Müllhaupt B; Agarwal K; Angus P; Yoshida EM; Colombo M; Rizzetto M; Dvory-Sobol H; Denning J; Arterburn S; Pang PS; Brainard D; McHutchison JG; Dufour JF; Van Vlierberghe H; van Hoek B; Forns X;
    Lancet Infect Dis; 2016 Jun; 16(6):685-697. PubMed ID: 26907736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Health Care System.
    Ioannou GN; Beste LA; Chang MF; Green PK; Lowy E; Tsui JI; Su F; Berry K
    Gastroenterology; 2016 Sep; 151(3):457-471.e5. PubMed ID: 27267053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease.
    Charlton M; Everson GT; Flamm SL; Kumar P; Landis C; Brown RS; Fried MW; Terrault NA; O'Leary JG; Vargas HE; Kuo A; Schiff E; Sulkowski MS; Gilroy R; Watt KD; Brown K; Kwo P; Pungpapong S; Korenblat KM; Muir AJ; Teperman L; Fontana RJ; Denning J; Arterburn S; Dvory-Sobol H; Brandt-Sarif T; Pang PS; McHutchison JG; Reddy KR; Afdhal N;
    Gastroenterology; 2015 Sep; 149(3):649-59. PubMed ID: 25985734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.
    Afdhal N; Reddy KR; Nelson DR; Lawitz E; Gordon SC; Schiff E; Nahass R; Ghalib R; Gitlin N; Herring R; Lalezari J; Younes ZH; Pockros PJ; Di Bisceglie AM; Arora S; Subramanian GM; Zhu Y; Dvory-Sobol H; Yang JC; Pang PS; Symonds WT; McHutchison JG; Muir AJ; Sulkowski M; Kwo P;
    N Engl J Med; 2014 Apr; 370(16):1483-93. PubMed ID: 24725238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trial.
    Andrieux-Meyer I; Tan SS; Thanprasertsuk S; Salvadori N; Menétrey C; Simon F; Cressey TR; Said HRHM; Hassan MRA; Omar H; Tee HP; Chan WK; Kumar S; Thongsawat S; Thetket K; Avihingsanon A; Khemnark S; Yerly S; Ngo-Giang-Huong N; Siva S; Swanson A; Goyal V; Bompart F; Pécoul B; Murad S
    Lancet Gastroenterol Hepatol; 2021 Jun; 6(6):448-458. PubMed ID: 33865507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Ledipasvir Plus Sofosbuvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2 Infection.
    Gane EJ; Hyland RH; Yang Y; Svarovskaia E; Stamm LM; Brainard DM; McHutchison JG; Stedman CAM
    Gastroenterology; 2017 May; 152(6):1366-1371. PubMed ID: 28137593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.